Article info
PDFDrug information (i. anti-infectives, ii. cytostatics, iii. others)
DGI-022 Cost-Efficacy Analysis of Cabazitaxel For the Treatment of Hormone-Refractory Metastatic Prostate Cancer Patients
Citation
DGI-022 Cost-Efficacy Analysis of Cabazitaxel For the Treatment of Hormone-Refractory Metastatic Prostate Cancer Patients
Publication history
- First published March 12, 2013.
Online issue publication
October 20, 2020
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions